Cargando…

Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies

The development of hybridoma technology for producing monoclonal antibodies (mAbs) by Kohler and Milstein (1975) counts as one of the major medical breakthroughs, opening up endless possibilities for research, diagnosis and for treatment of a whole variety of diseases. Therapeutic mAbs were introduc...

Descripción completa

Detalles Bibliográficos
Autores principales: Doevendans, Erik, Schellekens, Huub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6640699/
https://www.ncbi.nlm.nih.gov/pubmed/31544827
http://dx.doi.org/10.3390/antib8010021